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doi:10.1016/j.bjps.2008.11.119Summary A syndrome now known as EhlerseDanlos, comprising laxity and fragility of the
skin associated with hypermobility of the large joints, was published in 1892 by Tschernogo-
bow. EhlerseDanlos type VIIA is an extremely rare form of the syndrome. While the UK-based
EhlerseDanlos Support Group recommends that the surgical management of patients with Eh-
lerseDanlos VIIA should be carried out in conjunction with a plastic surgeon, there is nothing in
the plastic surgery literature regarding this syndrome. The management of patients suffering
from EhlerseDanlos VIIA is highly complex, as a result of the breadth of genetic and phenotypic
presentations, and resulting complications. We present a review of the literature regarding
this syndrome and, in particular, the surgical problems that may be encountered. A case report
outlining our experience of successfully managing this condition is also presented.
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ublished by Elsevier Ltd on behalf ofEhlerseDanlos syndrome (EDS) comprises a group of genet-
ically, biochemically and clinically diverse, heritable
connective tissue disorders. The first comprehensive
description of the syndrome comprising laxity and fragility
of the skin associated with hypermobility of the large joints
was published in 1892 by Tschernogobow,1,2 and later
both Ehlers and Danlos,3e5 who were Danish and FrenchBritish Association of Plastic, Reconstructive and Aesthetic Surgeons.
590 I.S. Whitaker et al.dermatologists, respectively, published their observations
independently in the first decade of the 20th century.
Subsequently, significant advances in modern biochemistry,
DNA analysis and genetics have expanded the range of clin-
ical phenotypes and pathogenesis. At least one in 5000 indi-
viduals worldwide suffer from EDS.6 Skin fragility, bleeding
diathesis, excessive bruising, poor wound healing and atro-
phic scarring are common to all EDS subtypes, sometimes
causing clinical complications relevant to plastic surgery.7,8
EDS type VIIA is extremely rare and only a handful of cases
are known worldwide. The UK-based EhlerseDanlos Support
Group,9 which publishes extensive medical information
for families of those suffering from EDS, recommends that
the surgical management of patients with EDS type VIIA
should be in conjunction with a plastic surgeon to optimise
soft-tissue management. To our knowledge, there is
nothing in the plastic surgery literature regarding the
management of patients suffering from EDS type VIIA. We
describe our experience of managing this case, make
appropriate recommendations and discuss the management
of EDS type VIIA in the context of other EDS type VII
subtypes.Figure 1 Postoperative photograph at 6 months.Case report
A 5-year-old Caucasian male with EDS type VIIA was
referred to the department of plastic and reconstructive
surgery from the spinal orthopaedic surgery service. He
required spinal surgery and growing rod insertion to
correct a severe progressive scoliosis. The spinal surgery
team had consulted the EhlerseDanlos Society, and its
medical advisory team had advised management to
continue in conjunction with plastic surgeons as a result
of the known issues with skin and healing. A combined
procedure (with orthopaedic and plastic surgeons) was
performed to insert the growing rods at the University
Hospital. During preparation of the patient in the anaes-
thetic room, the medial left thigh was unexpectedly
lacerated by the application of an adhesive electrode.
Intra-operatively, as expected, the patient had severe
ligamentous laxity. A straight 8-cm incision was made to
gain access to the thoracic vertebrae, and a curved 11-cm
incision was used to gain access to the lumbar vertebrae.
During the procedure, the patient developed ecchymoses
with minimal skin pressure. Both the thigh laceration and
the surgical incisions were closed in two layers using 4/
0 Vicryl and 4/0 Moncryl by the plastic surgery team.
The sutured incisions were supported with 2.54-cm Steri-
strip and Mepore. During the procedure, the patient
required 435 ml of colloids and 400 ml of crystalloids to
maintain normovolaemia. Following the procedure,
340 ml of blood was administered in PICU due to postoper-
ative anaemia and increasing base deficit. The 24-h post-
operative stay in PICU was otherwise non-eventful, and
the wound drained 120 ml in total. Intra-operative and
postoperative antibiotics were administered. The patient
gained a total of 5.5 cm height as a result of surgery.
In spite of an obvious degree of ligamentous laxity and
skin fragility, the operative course was smooth, and no
specific problems with haemostasis or skin closure were
encountered.Postoperatively, the Steri-strips and Mepore were
retained for 4 weeks, and at 1-month outpatient follow-
up, the wounds had healed. During this time, the skin had
developed mild erythema from the adhesive dressing.
Once the erythema had completely settled, 2.54-cm
Micropore was placed longitudinally along the wound
and changed daily for a further 2 months to support the
wound edges. At 3-month follow-up, the wound was
maturing satisfactorily and was pink and flat, with minimal
stretching. The 2.54-cm Micropore was continued for
a further month, at which point it was stopped by the
parents due to skin irritation. At 6-month follow-up, both
scars were pink and flat, with no evidence of hypertrophy.
The lower scar was slightly stretched in the middle-to-
lower two-thirds (see Figures 1e3).
Discussion
EDS comprises a broad group of connective tissue disorders
which share defects in the synthesis and cross-linking of
collagen.10e13 This results in an array of clinical manifesta-
tions, including fragile and hyperextensible skin, joint
hypermobility, easy bruising and a propensity to scar-
ring.11,14 Several classification systems for the EDS have
been described, which has contributed to some discrep-
ancies in classification and nomenclature.14e16 Between
six and ten EDS subtypes have been described, variably
classifying these types according to their molecular pathol-
ogies, clinical phenotypes and disease associations.
Despite variation in terminology, each of these systems
shares common descriptions of EDS type VII, the focus of
Figure 2 Postoperative photograph of the healed scar on the
upper back at 6 months. The scar is pink and flat, with no
evidence of hypertrophy.
Figure 3 Postoperative photograph of the healed scar on the
lower back at 6 months. The scar is pink and flat, with no
evidence of hypertrophy, although it is slightly stretched in
the middle-to-lower two-thirds.
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molecular pathology and clinical presentation. Its clinical
characteristics comprise early-onset congenital hip dislo-
cation, ligament laxity, scoliosis, short stature and osteo-
porosis.11,12,14EDS type VII has been termed the
‘arthrochalasis multiplex congenital’ type, with these
phenotypes caused by defective type I collagen synthesis,
a major structural protein in connective tissues.10
The molecular changes in EDS type VII result in defects in
the conversion of type I procollagen to collagen. Type I
collagen is a protein containing two a1(I) chains and one
a2(I) chain, which are coded by the genes COLIA1 and
COLIA2.18,19 It is the most abundant structural protein in
the mammalian body. Type I collagen is synthesised as
a precursor protein, procollagen, which contains additional
peptide sequences at both ends of the molecule which
require proteolysis in order to produce functional collagen.
EDS type VII results from failure of this enzymatic cleavage
by the protease, ‘procollagen N-proteinase’.10,18e20 Other
studies have also implicated differing molecular mecha-
nisms in the pathogenesis of EDS type VII, including defects
in the production of type V collagen21 and defects in the
fibronectin extracellular matrix of fibroblasts.22,23
While EDS type VII is caused by abnormal splicing of exon
6 in the COLIA1 or COLIA2 gene, it can be further classified
according to its molecular basis into types VIIA, VIIB and
VIIC.10 EDS type VIIA results from defects in the COLIA1
gene that encodes the proa1(I) chains of type 1 procolla-
gen.10,24,25 EDS type VIIB results from defects in the COLIA2gene that encodes the proa2(I) chains of type 1 procolla-
gen.10,26e34 EDS type VIIC is due to mutations in the
protease itself, which is generally the more severe pheno-
type.10,35e39 EDS types VIIA and VIIB are often grouped
together, known as the ‘arthrochalasia’ type of EDS, while
EDS type VIIC is known as the ‘dermatosparaxis’ type of
EDS, as it is similar to its counterpart in animals.10,40,41 Of
note, there are only a small number of cases of EDS type
VII worldwide.
Arthrochalasia-type EDS disorders are autosomal domi-
nant and present with bilateral hip dislocation, severe joint
and ligamentous laxity and recurrent joint dislocations and
subluxations.14,19 In addition, there are specific issues in
the treatment of EDS type VIIA that are specific to the
plastic surgeon.
Collagen, an essential component of skin and intimately
involved in healing and scar formation, is impaired in EDS
type VIIA. Skin is fragile and hyperextensible and has
a specific diagnostic disorganisation of collagen fibril
assembly, seen as misshapen collagen fibres on micros-
copy.10,12 (see Figure 4a and b). Even when they appear
normal on electron microscopy, the collagen fibrils are
uniformly smaller than normal.42 The fibril disorganisation
and reduction in size and content of collagen have also
been demonstrated on the routine microscopy of dermal
skin biopsies in these patients.43,44
Skin manifestations also include poor wound healing,
‘cigarette paper scarring’ (broad and thin scars), easy
Figure 4 Transversely sectioned cutaneous collagen fibrils
from EDS VII skin compared with normal control. (a) Micros-
copy of regularly sized, circular collagen fibrils in a control
patient (Magnification 50 000). (b) Microscopy of misshapen,
thinner angulated fibrils in the EhlerseDanlos Type VII patient.
These differences indicate mispacking and assembly of the
fibrils caused by the persisting pNalpha1(I) extensions (Magni-
fication 55 000).
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Unique cutaneous manifestations have also been reported
in some series, including the prominent ‘criss-cross
patterning of the hands and feet’ described in several
patients,19 a significant amount of redundant skin12,19 and
skin discolouration.12 While these effects have been widely
reported in case series, the involvement of plastic surgeons
and, in particular, guidelines for plastic surgical manage-
ment, has not been reported.10,12,14,19,45
In patients with EDS type VIIA, plastic surgical compli-
cations should be anticipated, and prepared for.46e48 These
patients should be handled intra- and postoperatively with
extreme care, due to skin fragility and bleeding tendencies.
The pathological skin changes described previously
mandate meticulous care in handling tissues and wound
closure, and Steri-strips or retention sutures should be
used to minimise skin tension. If non-absorbable skin
sutures are used, they should be left in longer than normal.
Although evidence for this care is notably lacking, our case
report highlights the success of this approach, and, in view
of the known pathophysiology of the condition, it would be
unwise to treat wounds otherwise.Due to the propensity of patients with EDS to bleed, it is
sensible to cross-match adequate amounts of blood and
rule out concomitant coagulopathies.46 Regional anaes-
thesia, arterial lines and central venous catheters should
be avoided as much as possible, as these patients are at
significantly increased risk of haematoma formation. If
arterial blood gas sampling is necessary, a needle or cath-
eter as small as possible should be used.46 While the
vascular type of EDS is at greatest risk for bleeding compli-
cations,49e53 complications related to bleeding and
vascular fragility are common to all types of EDS, and
indeed the use of blood products and coagulation factors
to correct bleeding tendencies in these patients have
been described.
It has been postulated in the literature suggesting that
EhlerseDanlos patients have a ‘resistance’ to local anaes-
thetics. The effects of local anaesthetics are complex and
depend on the individual chemical properties of the agent
and a number of tissue factors. Studies have suggested that
the lack of effectiveness of local anaesthetic solution is not
due to rapid dispersal of solution in EhlerseDanlos patients,
as is often assumed.57
While guidelines for management are lacking, the sugges-
tions made are well supported by the underlying patholog-
ical changes in EDS type VII. Additional therapeutic targets in
the healing of skin have also been suggested in both
laboratory and clinical studies. Dexamethosone has been
suggested as a means to improving the disordered organisa-
tion of fibronectin extracellular matrix in the fibroblasts of
these patients as described earlier. In laboratory studies, it
has been shown to correct the disordered fibroblasts,54 and,
in clinical studies, it has been shown to do the same and to
result in improved healing.55,56 While medical therapies
are still experimental, the importance of treatment lies in
the diagnosis of the syndrome and the adequate planning
in consideration of potential complications.
In our case, the patient experienced only minor skin
fragility and bruising intra-operatively, with excellent
wound healing and few or no problems with insertion of
the orthopaedic rods. At 3-month follow-up, the scars had
healed satisfactorily, following careful wound closure and
the use of supportive measures for 3 months postopera-
tively. Our patient had a significant improvement in his
quality of life, with improved posture and a height gain of
5.5 cm. Future planning to partially re-open his incisions to
extend the ‘growing’ rods at about 18 months and a similar
wound closure regimen with the combined input of ortho-
paedics and plastic surgery will be undertaken to optimise
outcomes.
EDS Type VII is an extremely rare condition affecting the
synthesis of type I collagen and affecting connective tissues
throughout the body. Implications for the plastic surgeon
include effects on skin healing and scarring and the
propensity for bruising and bleeding complications. As
such, we suggest the inclusion of plastic surgical input in
the preoperative planning for any patient with EDS type VII
undergoing surgery of any kind.Conflict of interest
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Ehlers-Danlos syndrome. Br J Plast Surg 2000 Jun;53:308e12.SURGICAL TIPA simple method for fishing out the umbilicus in
abdominoplasty surgery
Retrieving the umbilicus after abdominoplasty is, some-
times, not an easy task and may be embarrassing to thesurgeon. We found that tying the umbilicus to a suture
and bring the suture through the abdominal wall can
exactly position it at the centre of the neoumbilicus
before closing the abdominoplasty wound (Figure 1a).
Subsequently, the umbilicus can be easily brought out
by excising a small piece of skin around the stitch (Fig-
ure 1b) to be finally sutured into its new location. This
will save time otherwise spent in fishing out the buried
umbilicus which can prove difficult to the extent that it
may inevitably lead to the undoing of the procedure so
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